France: New Law Applicable to Clinical Trials and Studies ("Loi Jardé")

Contributed by Carol A.F. Umhoefer and Michaell Smith

On March 5, 2012, France adopted a new law on clinical trials and studies (Law No. 2012-300) (the "Law").  The Law, which has been in discussion since early 2009 and which will become effective once the implementing measures have been published in the Official Journal of the French Republic, is intended to encourage the development of clinical trials and studies in France, while at the same time clarifying the applicable legal framework.  Many provisions of the Law are awaiting implementation by decree and ministerial decision ("arrêté") which the French Agency for Safety of Health Products (Agence Nationale de Sécurité Sanitaire des Produits de Santé - AFSSAPS) expects to be issued no sooner than summer 2012.  

Continue reading for highlights of the principal developments.

Continue Reading

IOM Issues Report Recommending Steps To Bolster Product Safety Worldwide

global cuisine.jpgContributed by Rebecca Jones McKnight and So-Eun Lee

Last month, on April 4, 2012, the Institute of Medicine (IOM) issued a report titled “Ensuring Safe Foods and Medical Products Through Stronger Regulatory Systems Abroad.”  The report recommends 13 steps that the U.S. Food & Drug Administration (FDA) and other organizations can take over the next few years to bolster product safety systems around the globe.  See our prior discussion of related topics here and here.

Continue Reading

Warning Letters Matter: Nov. 2011 Summary

FDA Warning Letters through November 2011 are now publicly available.  Below is our summary of recent Warning Letters of particular interest. 

  • FDA cited one company for marketing chocolate as an unapproved new drug The unauthorized health claims involved brain injury, cardiac mortality and tooth decay, among others.  The company was also cited for food cGMP violations involving failure to properly clean the manufacturing facility.
  • FDA cited a company misbranded cosmetics, one of which was a collagen cream containing “dribble of the snail,” because the ingredient was not declared in accordance with labeling requirements.
  • FDA continues to monitor social media, and cited one company for promoting unapproved new drugs on its Facebook page.
  • FDA cited one company for unapproved new devices in connection with its HIV saliva rapid screen test IVD. 
  • In a relatively unusual letter, FDA cited a hospital for repeat violations of mammography quality standards and indicated that, if the violations were not corrected, the agency may take additional action, including charging the hospital for the cost of on-site monitoring, civil money penalties of up to $10,000, and suspension or revocation of the hospital’s FDA certificate.
  • FDA continues to focus on Good Manufacturing Practices and posted warning letters for the following devices: IVF devices, pediatric and adult temperature probes, dental x-ray automatic film processors, spinal and knee system devices, infant and neonatal CO2 filter devices, soft contact lenses, a TENS stimulator, and cervical and lumbar traction devices, dental bridge frameworks, nebulizers and thermometers, a therapeutic (incentive) spirometer, and compression devices. 

The statistics are:

  • 12 letters re cGMP pharma violations;
  • 11 letters re cGMP device violations;
  • 7 letters re unapproved new drugs (Nature’s Rite, LLC, Algonot, LLC, Focus Laboratories, Inc., Altaire Pharmaceuticals, Inc., Rose Stone Enterprises dba Hub Pharmaceuticals, LLC, NanoLiposomal Nutritionals, and Crescendo Therapeutics LLC (including postmarketing adverse event reporting violations)); 
  • 3 letters re unapproved new devices and new uses (Electrostim Medical Services Inc. dba EMSI, Topcon Corporation and Osmed GmbH (including cGMP violations));
  • 3 letters re drug studies (Columbia University Medical Center, Laura A. Teasley, M.D., and Leslie E. Diaz, M.D.);
  • 3 letters re medical device reporting (National Therapy Products, Inc. (including cGMP violations), Respironics, Inc., and Laser Eye Care of California, LLC);
  • 3 letters re tobacco products (AD and AD International, Ltd., IndoCigs and Vitalie Rotaru);
  • 2 letters re mammography standards (Middlesboro Appalachian Regional Hospital and Eiber Radiology, Inc.);
  • 2 letters re unapproved new devices (SterilMed, Inc., and OraWell USA (including cGMP violations));
  • 1 letter re unapproved dietary supplements (Nordimex, LLC (including cGMP and labeling violations));
  • 1 letter re food as unapproved new drug (TCHO Ventures, Inc. (including cGMP violations for food)); and
  • 1 letter re postmarketing adverse event reporting (Jazz Pharmaceuticals, Inc.).

France Adopts New Law on Safety of Health Products

France has adopted a new law reinforcing the safety of health products.

This law was adopted in large part in an effort to restore public trust in the French pharmaceutical and medical device regulatory system, a confidence which has been shaken by such events as the Mediator® scandal.

The new law creates a new pharmaceutical regulatory body, Agence Nationale de Sécurité du Médicament et des Produits de Santé; aims to improve transparency around conflicts of interest; and reinforces pharmacovigilance.

Click here to read more.

Senator Kay Hagan (D-NC) Introduces TREAT Act to Speed Up FDA Review Process

Contributed by John Slotman as part of our Health on the Hill series.

As Congress continues its work on FDA funding and the reauthorization of user fee programs such as the Prescription Drug User Fee Act (PDUFA) and the Medical Device User Fee and Modernization Act (MDUFMA), there is no shortage of new pieces of legislation Members of Congress are endeavouring to attach to these must-pass legislative vehicles.  The latest effort in this vein was introduced this week by U.S. Senator Kay Hagan (D-NC). 

Sen. Hagan’s legislation, S. 2113, the Transforming Regulatory Environment to Accelerate Access to Treatments (TREAT) Act, would target a common industry complaint of the U.S. Food and Drug Administration (FDA):  the drug and device approval process is slow, uncertain, and in need of reform. 

While the focus of the TREAT Act is on accelerated approval of treatments for rare diseases, the legislation contains a number of provisions affecting the medical innovation industry overall.  Specifically, the TREAT Act would look to reform a number of internal FDA processes by giving the FDA Commissioner additional authority to utilize conflict of interest waivers for individuals serving in the FDA Advisory Committee structure.  Other provisions in the legislation would also mandate the inclusion of patient advocate and disease research organizations in Advisory Committee reviews and promote innovation within the FDA the creation of Chief Medical Policy Officer positions within the FDA branches responsible for drug, device, and biologic approvals. 

The fate of user fee add-on proposals such as the TREAT Act is as of yet undetermined.  Testifying earlier this week before the House Energy and Commerce Committee Subcommittee on Health, FDA Center for Devices and Radiological Health director Jeffrey Shuren argued against the addition of extraneous provisions to user fee legislation, stating that piling non-germane items on user fee acts could lead to “unintended consequences” such as slowed review times. 

Nevertheless, with limited legislative vehicles this year and a growing number of FDA-related Congressional priorities on issues such as Advisory Committee waivers, drug pipeline safety, and drug shortages, the addition of unrelated items to user fee reauthorizations seems inevitable.  Whether the TREAT Act is among those unrelated items attached to PDUFA and MDUFMA reauthorization remains to be seen.  PDUFA and MDUFMA will expire on October 1, 2012, without further Congressional action.  

What Did 2011 Mean for False Claims Act Recoveries by DOJ?

2011 marked the second year in a row that DOJ surpassed $3 billion in recoveries under the False Claims Act.

In December, DOJ reported:

"Enforcement actions involving the pharmaceutical industry were the source of the largest recoveries this year.  In all, the department recovered nearly $2.2 billion in civil claims against the pharmaceutical industry in fiscal year 2011, including $1.76 billion in federal recoveries and $421 million in state Medicaid recoveries."

Pharmaceutical companies, take note.

And it's not just the False Claims Act to think about.

In 2011 DOJ obtained 21 criminal convictions and $1.3 billion in criminal fines, forfeitures, restitution, and disgorgement under the Food, Drug and Cosmetic Act .

Stem Cell Research and Patentability in the EU and U.S.

DataTransfer.jpgEarlier this month DLA Piper's Lisa A. Haile and Aaron Fountain teamed up with European colleagues Philippa Montgomerie and Grant Strachan to weigh in on current differences in the patentability of stem cells in Europe and the United States. 

You can find the article here.

 

HIPAA and Emerging Technologies

DocWithiPhone.jpgContributed by Marcia Augsburger and Scott Koller.

The Health Insurance Portability and Privacy Act of 1996 (HIPAA) is 15 years old this year – still acting a bit like an uncertain, wide-eyed teenager responding to new developments. Although more mature, clarified by regulations, and supplemented by the HITECH Act, at its core HIPAA has remained relatively unchanged since its enactment. Societal changes implicating HIPAA, however, have been significant. Over the past five years alone, we saw the rise of Facebook, the domination of Google, and the introduction of powerful personal electronic devices such as Apple’s iPhone and iPad. In addition, technologies such as cloud computing, wireless communication, and telemedicine have reached a level of reliability and affordability that has allowed healthcare providers to expand their reach and services. With every emerging technology, the specter of HIPAA compliance remains a key concern, while its application becomes more murky. 

HIPAA was designed to be technology neutral. Accordingly, the statute is worded in terms of principles of compliance instead of specific measures to be implemented. While this permits flexibility so that the law can continue to be relevant as time and technology progress, it also creates ambiguity. Indeed, so ambiguous are HIPAA statutes that there continues to be a debate over its application to a technology as ubiquitous as email.

Nonetheless, HIPAA offers a methodical, step-by-step process for reviewing new programs, applications, and technologies to ensure technical safeguards are in place. The safeguards cover five areas:  Access controls; audit controls; integrity controls, authentication, and transmission security.  This article addresses each of these, and explains the challenges they present in evaluating compliance issues as applied to emerging technologies.   

I.          Access Controls

The first area addressed by the Technical Safeguards deals with Access Control. HIPAA requires the covered entity (CE) or business associate (BA) to implement technical policies and procedures that allow only authorized persons access to protected health information (PHI).[i] Apart from this rather broad requirement, HIPAA left the implementation of access controls to CEs and BAs, who may select the technologies that best fit their organizations, so long as the controls are consistent with the four areas of focus within the Access Control standard. The controls must include a unique user identification system, emergency access procedure, automatic termination with inactivity, and encryption.

            A.        Unique User Identification (Required). HIPAA requires each user to be assigned a unique name or number.[ii] The purpose is to allow the CE to track specific user activity and to hold those users accountable for functions performed while logged into covered systems. When selecting an identification scheme, CEs and BAs should consider how the unique identifier will be used internally and externally. If the identifier is used primarily within an organization by employees, then an entity may use the employee name or similar variation (e.g., jsmith). However, using a random set of numbers and characters may be preferred if the name itself may express PHI (e.g., jsmith on a list of Alcoholics Anonymous members).[iii]

System designers must also be careful to limit the use of the selected unique identifiers. Software programmers for Apple’s iPhone learned this lesson the hard way when, at Apple’s suggestion, they identified specific users using the unique device identifiers (UDID) that were built-into iPhones.[iv] These UDIDs were accessible by other apps, some of which had significantly less security in place for the protection of personal information.  By using the same UDID, the protection accorded that identifier is only as good as the least secure app using the identifier. This illustrates the advisability of avoiding a user identification scheme that other applications or software also use.   

            B.        Emergency Access Procedure (Required). The CE must have a procedure in place for obtaining necessary electronic PHI (ePHI) during an emergency.[v] In an emergency, especially where a natural disaster cuts off power, electronically stored information is imperiled. After all, the lifeblood of technology is electricity. To determine the need for back-up generators or paper files, CEs and BAs should evaluate from the outset what information will be needed in an emergency for patient care and treatment and how best to create redundancies to preserve it. 

            C.        Automatic Logoff (Addressable)[vi]. When reasonable and appropriate, a CE must implement electronic procedures that terminate an electronic session after a predetermined period of inactivity.[vii] This is particularly important when dealing with applications for personal electronic devices such as smart phones, which are highly portable and can be easily misplaced. While HIPAA does not mention a specific timeframe, the termination or logoff function should take into account the likelihood of an unauthorized user encountering the system. In addition, screensavers and/or automatic logoffs, which are built into many systems, should always be enabled. 

            D.        Encryption and Decryption (Addressable). To take advantage of a HIPAA “safe harbor,”[viii] CEs must use encryption to protect data from unauthorized access.[ix] Of the four Access Control safeguards, encryption is by far the most difficult to implement. Whereas a unique identifier, an emergency back-up, and an automatic log-off are fairly easy to implement, encryption involves the use of complex algorithms and a series of confidential “keys” used to code or access the data. 

At the core of every encryption scheme is a mathematical algorithm, the strength of which depends on its key-length size or bits. HIPAA does not mandate the use of any specific type or strength of encryption.  Most financial institutions use 256 bit encryption for banking transactions, while several reputable e-commerce sites use key lengths of 128 bits to process credit cards. Although HIPAA permits flexibility, it would be inadvisable to implement a key shorter than 128 bits. To put this in perspective, it would take a modern computer 149,745,258,842,898 years to break a 128 bit key whereas the same computer could crack a 64 bit key in approximately four minutes.[x] 

Even if a lengthy key is used, a mistake or flaw in the mathematical formula can render the entire encryption scheme vulnerable. New or customized encryption schemes pose a greater risk of discoverable flaws than encryption algorithms that have been certified by the National Institute of Standards and Technology (NIST).[xi]  This may explain why using NIST standards for encryption qualify as a “safe harbor” under HIPAA.[xii]

In addition to using flawed or short encryption keys, a common mistake in encryption is failure to secure the key itself. When online whistle-blower website WikiLeaks distributed classified government cables to the press, it used a top of the line AES-256 bit encryption but failed to secure the key. The key was published, rendering the entire encryption scheme useless. The security surrounding encryption keys, including old and retired keys, should receive the same level of scrutiny as the data they are protecting. 

This is part one of a three part series discussing HIPAA and emerging technologies.  Part two explores Authentication, Audit and Integrity controls under HIPAA. 

 

 

 


[i] 45 C.F.R. § 164.312(a) for covered entities and business associates under the HITECH Act. 

[ii] 45 C.F.R. § 164.312(a)(2)(i).

[iii] Department of Health & Human Services (DHHS), Security Standards. Published 5/2002, revised 3/2007 (“A randomly assigned user identifier is more difficult for an unauthorized user (e.g., a hacker) to guess, but may also be more difficult for authorized users to remember and management to recognize.” 

[iv] Hardawar, Devindra, Apple phasing out iOS UDID access to solve privacy woes. Retrieved September 18, 2011, from http://venturebeat.com/2011/08/23/ios-5-udid-privacy/.

[v] 45 C.F.R. § 164.312(a)(2)(ii).

[vi] DHHS provides flexibility to covered entities. stating whether a specification is "required" or "addressable." If the specification is "required," the CE must implement the specification as stated in the Security Rule. If the specification is "addressable" then the CE must:1. Assess whether the specification is a reasonable and appropriate safeguard in its environment and likely to contribute to protecting the entity's electronic protected health information; and 2. Implement the specification or document why it would not be reasonable and appropriate and implement an equivalent alternative measure if reasonable and appropriate. DHHS, What is the difference between addressable and required implementation specifications in the Security Rule? Retrieved September 19, 2011 from http://www.hhs.gov/ocr/privacy/hipaa/faq/securityrule/2020.html.

[vii] 45 C.F.R. § 164.312(a)(2)(iii).

[viii] Specifically, HHS has stated that if an organization uses recommended technologies and methodologies that render PHI unusable, unreadable, or indecipherable to unauthorized individuals, then that PHI would not qualify as “unsecured” PHI for purposes of the breach notification requirements, which only applies to “unsecured” PHI. “Guidance Specifying the Technologies and Methodologies That Render Protected Health Information Unusable, Unreadable, or Indecipherable to Unauthorized Individuals for Purposes of the Breach Notification Requirements Under Section 13402 of Title XIII (Health Information Technology for Economic and Clinical Health Act) of the American Recovery and Reinvestment Act of 2009; Request for Information,” 74 Fed. Reg. 19006 (April 27, 2009)

[ix] 45 C.F.R. § 164.312(a)(2)(iv)

[x] Clayton, Richard, Brute force attacks on cryptographic keys. Retrieved September 18, 2011, from http://www.cl.cam.ac.uk/~rnc1/brute.html.

[xi] National Institute of Standards and Technology, Computer Security Division. Retrieved September 18, 2011 from http://csrc.nist.gov/.

[xii] “Guidance Specifying the Technologies and Methodologies That Render Protected Health Information Unusable, Unreadable, or Indecipherable to Unauthorized Individuals for Purposes of the Breach Notification Requirements Under Section 13402 of Title XIII (Health Information Technology for Economic and Clinical Health Act) of the American Recovery and Reinvestment Act of 2009; Request for Information,” 74 Fed. Reg. 19006 (April 27, 2009).

Incentives Change Behavior

40893b8zcr127ya[1].jpgContributed by Marcia L. Augsburger as part of our ongoing Wellness Matters series.

Last week, USA Today reported that 1/2 of all Medicare patients took advantage of the new benefit offered in section 4103 of the Patient Protection and Affordable Care Act -  annual wellness visits, free of co-pays and deductibles, during which physicians administer comprehensive health risk assessments and design personalized prevention plans.  In late November, 2011, the New York Times reported that monetarily incentivizing employees to stop smoking works.  These reports support existing overwhelming evidence that incentives, such as reduced health care premiums, and waivers of co-pays, and deductibles, really do change behaviors.  Despite critics' speculation to the contrary, people will do what's good for them if it's free or they can make money.  

Specifically, the New York Times reported that "more and more employers are demanding that workers who smoke, are overweight, or have high cholesterol shoulder a greater share of their health care costs, a shift toward penalizing employees with unhealthy lifestyles rather than rewarding good habits."  This is a mischaracterization of what the employers referenced are really doing.  Companies like Safeway, Home Depot, PepsiCo, Lowe's, General Mills, and Wal-Mart are actually incentivizing their employees to improve their health by offering discounts to those who make lifestyle changes that dramatically reduce their risk of illness.  The New York Times chooses to characterize this as punishing those who do not take advantage of the incentives, but those who have improved their health because their employers offered tangible financial rewards in terms of cost-avoidance will tell you that the glass is half-full, not half-empty. 

If you are an employer worried about what ERISA, the ADA, and other laws have to say about offering incentives to your employees to improve their well-being, reviewing this "checklist" is a good place to start: Wellness Checklist.pdf

 Image: Ambro / FreeDigitalPhotos.net

Health Alert From Australia

AustraliaOhmega1982.jpgTo see the latest Health Alert from Australia, click here.